SecBot SecBot
DEFA14A ·Filed Jul 2, 2026

VXRT

Vaxart, Inc.
BULLISH
Impact 5/10
Horizonweeks Processed4mo ago SEC0001213900-26-075088
Proxy solicitation materials
Actionable Insight ▲ Bullish

The resolution of the proxy contest removes a key overhang and may stabilize the stock near term. Traders should watch for any disclosed board changes or additional details on the settlement, and then shift focus to upcoming clinical catalysts for the oral vaccine pipeline.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.6400
T+0 close · Jul 2, 2026 · via day close
Latest settled
−29.69%
T+60 · $0.4500
Vs SPY
−33.51%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 6 $0.6400entry
  2. T+1 · 4mo ago −1.64%α −2.51% · $0.6295
  3. T+5 · 4mo ago −14.69%α −16.05% · $0.5460
  4. T+20 · 4mo ago −14.22%α −14.52% · $0.5490
  5. T+60 · 7w ago −29.69%α −33.51% · $0.4500

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vaxart has reached an agreement with a group of shareholders to resolve its ongoing proxy contest, as announced via DEFA14A. The settlement removes near-term board-election uncertainty and allows management to focus on clinical and operational milestones for its oral vaccine platform.

Key Facts

  • Vaxart announced an agreement with a group of shareholders to resolve its proxy contest.
  • The company states it remains committed to corporate governance and shareholder engagement.
  • Management reiterated focus on upcoming clinical, regulatory and operational milestones.
  • The settlement follows a preliminary proxy filing (PREC14A) that indicated a contested director election from stockholder Daniel P. Houle.

Financial Impact

Not specified

Risk Factors

  • Terms of the shareholder agreement are not disclosed; any concessions could affect governance dynamics.
  • The company remains a clinical-stage biotech with no approved products, and pipeline execution risk persists.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001213900-26-075088
Document: 0001213900-26-075088-index-headers.html0001213900-26-075088
Document: 0001213900-26-075088-index.html0001213900-26-075088
Document: 0001213900-26-075088.txt0001213900-26-075088

Track record

23 reports on VXRT

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.3700 Now $0.3600 +2.70% settles Feb 4
  2. Oct 19, 202628d ago 8-K Neutral 3/10 Entry $0.4900 Now $0.3600 −26.53% settles Jan 15
  3. Jul 28, 202615w ago 8-K Neutral 2/10 Entry $0.4800 to $0.4900 Now $0.3600 −25.00% ▲ +2.08% −2.53% vs SPY
  4. Jul 7, 202618w ago 8-K Neutral 4/10 Entry $0.5500 to $0.4500 Now $0.3600 −34.55% ▼ −18.18% −21.27% vs SPY
  5. Jul 6, 202619w ago DEFA14A Neutral 5/10 Entry $0.6200 to $0.4540 Now $0.3600 −41.94% ▼ −26.77% −28.93% vs SPY
  6. Jul 2, 202619w ago DEFA14A Bullish 5/10 Viewing Entry $0.6400 to $0.4500 Now $0.3600 −43.75% ▼ −29.69% −33.51% vs SPY
  7. Jul 2, 202619w ago 8-K Neutral 4/10 Entry $0.6400 to $0.4520 Now $0.3600 −43.75% ▼ −29.38% −32.80% vs SPY
  8. Jun 26, 202620w ago DEFA14A Neutral 4/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  9. Jun 26, 202620w ago DEFA14A Neutral 3/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  10. Jun 26, 202620w ago 8-K Mixed 5/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 2, 2026